Vaccine development timelines and the current pipeline status strongly underpin the 94.5% market-implied probability against a hantavirus vaccine becoming available in 2026. No candidates have advanced to Phase 3 trials, with efforts limited to early-stage work such as Phase 1 DNA vaccines for Andes or Hantaan virus and recent preclinical structural designs from programs like NIH’s ReVAMPP. Typical regulatory pathways require years beyond initial immunogenicity data, and the virus’s sporadic nature limits large-scale efficacy testing. Recent May 2026 outbreaks have accelerated basic research interest but have not shortened these timelines. While an unforeseen emergency-use authorization or rapid approval in Asia could alter outcomes, the absence of near-term milestones makes such shifts improbable.